🇺🇸 FDA
Pipeline program

611

SSGJ-611-AD-III-01

Phase 3 small_molecule active

Quick answer

611 for Dermatitis, Atopic is a Phase 3 program (small_molecule) at Sunshine Biopharma with 3 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Dermatitis, Atopic
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials